U.S. markets close in 4 hours 50 minutes

Adicet Bio, Inc. (ACET)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
13.77+0.07 (+0.51%)
As of 11:07AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close13.70
Open13.55
Bid13.70 x 800
Ask13.84 x 1400
Day's Range13.44 - 13.90
52 Week Range6.02 - 21.70
Volume14,714
Avg. Volume130,196
Market Cap416.643M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.90
Earnings DateNov 05, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Adicet Bio Appoints Dr. Andrew Sinclair to its Board of Directors
    GlobeNewswire

    Adicet Bio Appoints Dr. Andrew Sinclair to its Board of Directors

    MENLO PARK, Calif. and BOSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Andrew Sinclair, Ph.D., to its board of directors. Dr. Sinclair will replace Erez Chimovits, who will step down from the Board of Directors. “Abingworth was a significant investor in our recent successful $152 million financing and we are extremely pleased to welcome Andrew, a highly-respected healthcare investor, to our Board of Directors,” said Chen Schor, President and Chief Executive Officer of Adicet Bio, Inc. “Andrew’s significant life science experience amassed throughout his career, both from the financial and scientific perspective, will be tremendously valuable to Adicet as we continue to advance ADI-001 into the clinic and expand our pipeline of ‘off-the-shelf’ gamma delta T cell product candidates. In addition, we would like to thank Erez for his five years of service and significant contributions to Adicet which have played an important role in advancing our strategic priorities.” “I am excited to join Adicet Bio’s Board of Directors,” said Andrew Sinclair. “Adicet’s allogeneic gamma delta T cell approach has a number of potential advantages over other cell therapy platforms and I look forward to working with my fellow board members and company management to advance Adicet’s corporate goals in the years ahead.” Dr. Sinclair is currently a partner and portfolio manager at Abingworth LLP, a life sciences investment group. He has been at Abingworth since 2008 where he has served in various positions focusing on investments in public and private biotech and pharmaceutical companies. Dr. Sinclair currently serves on the boards of directors of Soleno Therapeutics, Inc., Sierra Oncology and Verona Pharma plc. Prior to joining Abingworth, he was senior equity analyst, director, at HSBC Global Markets, where he was responsible for investment research in the mid-cap pharmaceutical sector. Previously, Andrew held biotechnology analyst positions at Credit Suisse and SG Cowen. Dr. Sinclair received his B.Sc. in Microbiology from King's College London and his Ph.D. in Chemistry and Genetic Engineering at the BBSRC Institute of Plant Science, Norwich. Andrew qualified as a chartered accountant with KPMG. About Adicet Bio, Inc. Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com. About Abingworth Abingworth is a leading transatlantic life sciences investment firm. Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top calibre management teams building world-class companies. Since 1973, Abingworth has invested in 172 life science companies, leading to 44 M&As and 69 IPOs. Our therapeutic focused investments fall into three categories: seed and early-stage, development stage, and clinical co-development. Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California), and Boston. Forward-Looking Statements This press release contains “forward-looking statements” of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to business and operations of Adicet including, but not limited to preclinical and clinical development of Adicet’s product candidates, including future plans or expectations for ADI-001 and potential therapeutic effects of ADI-001, the timing and outcome of discussions with FDA and other regulatory agencies, expectations regarding the design, implementation, timing, and success of its future clinical studies of ADI-001, and our growth as a company and the anticipated contribution of the members of our board of directors to our operations and progress. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including without limitation, Adicet’s ability to execute on its strategy; that positive results from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies; the expected impact and contribution of our board of directors and executives to our business as well as those risks and uncertainties set forth in the company’s most recent quarterly report on Form 10-Q and subsequent filings with the Securities and Exchange Commission. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Adicet’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Adicet’s most recent annual report on Form 10-K and our periodic reports on Form 10-Q and Form 8-K filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Adicet’s other filings with the SEC. All information in this press release is as of the date of the release, and Adicet undertakes no duty to update this information unless required by law. Adicet Bio, Inc.Investor and Media Contacts Anne Bowdidgeabowdidge@adicetbio.com Janhavi MohiteStern Investor Relations, Inc.212-362-1200janhavi.mohite@sternir.com

  • Adicet Bio, Inc. Announces Closing of $152 Million Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
    GlobeNewswire

    Adicet Bio, Inc. Announces Closing of $152 Million Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

    MENLO PARK, Calif. and BOSTON, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the closing of an underwritten public offering of 10,575,513 shares of its common stock, including the exercise in full by the underwriters of their option to purchase up to an additional 1,344,743 shares of common stock at a public offering price of $13.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses were approximately $137.5 million. All of the shares in the offering are to be sold by Adicet. In connection with the offering, Adicet entered into a stock purchase agreement with certain existing investors for $15.0 million of shares of its common stock at a price per share equal to the public offering price, with an initial closing for certain investors held simultaneously with the closing of the offering and a subsequent closing for certain additional investors. Guggenheim Securities, LLC acted as book-running manager for the offering. Canaccord Genuity LLC, Wedbush Securities Inc. and JMP Securities LLC acted as co-managers for the offering. The shares are being offered by Adicet pursuant to a shelf registration statement that was previously filed with, and subsequently declared effective on February 12, 2019 by, the U.S. Securities and Exchange Commission (SEC). A final prospectus supplement relating to and describing the terms of the offering was filed with the SEC on February 11, 2021. Copies of the final prospectus supplement and the accompanying prospectus relating to the offered securities may be obtained from Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Adicet Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. Adicet Bio, Inc.Investor and Media ContactsAnne Bowdidgeabowdidge@adicetbio.com Janhavi MohiteStern Investor Relations, Inc.212-362-1200 Source: Adicet Bio, Inc.

  • Adicet Bio to Participate in Upcoming Investor Conferences
    GlobeNewswire

    Adicet Bio to Participate in Upcoming Investor Conferences

    MENLO PARK, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that the company management will participate in three upcoming virtual investor conferences. Details of the events are as follows: Guggenheim Healthcare Talks 2021 Oncology Day, February 11-12, 2021Adicet’s management team will participate in virtual investor meetings at the conference on Friday, February 12, 2021. SVB Leerink Global Healthcare Conference, February 22-26, 2021 Chen Schor, President and Chief Executive Officer, will deliver a presentation on Wednesday, February 24, 2021 at 5:00 PM ET. H.C. Wainwright Global Life Sciences Conference - March 9-10, 2021Registered attendees can access the recorded presentation on-demand starting March 9, 2021 at 6:00 AM ET for the duration of the conference. A live audio webcast of the SVB Leerink presentation can be accessed on the Investors section of Adicet Bio’s website at https://investor.adicetbio.com. An archived replay will be available for 30 days following the presentation. About Adicet Bio, Inc.Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com. Adicet Bio., Inc.Investor and Media Contacts Anne Bowdidgeabowdidge@adicetbio.com Janhavi MohiteStern Investor Relations, Inc.212-362-1200janhavi.mohite@sternir.com